Platelet Sub-study of the Neomindset Trial

Inclusion criteria: Age >=18 years; Clinical presentation compatible with acute coronary syndrome with onset < 24 hours before admission; Successful percutaneous coronary intervention(s) of all target lesions (culprit and non-culprit) with new-generation drug-eluting stents; Length of stay in hospital at randomization < 96 hours; Subjects will be informed about the nature of the study and must agree to comply and give an informed consent in writing using a form approved in advance by the local Ethics Committee. Exclusion Criteria: Acute coronary syndrome on index admission treated in a conservative way or by unsuccessful percutaneous intervention or surgically; Presence of residual lesions which are likely to require future treatment in the next 12 months; Fibrinolytic therapy < 24 hour before randomization; Need of oral anticoagulation with warfarin or new anticoagulants; Chronic bleeding diathesis; Active or recent major bleeding (in-hospital); Prior intracranial hemorrhage; Ischemic cerebrovascular accident < 30 days; Presence of brain arteriovenous malformation; Index event of non-atherothrombotic etiology (i.e., stent thrombosis, coronary embolism, spontaneous coronary artery dissection, myocardial ischemia due to supply/demand imbalance); Potential or scheduled cardiac or non-cardiac surgery in the next 12 months; Platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3; Total white blood count < 3,000 cells/mm3; Suspected or documented active liver disease (including laboratory evidence of hepatitis B or C); Receiver of heart transplant; Known allergies or intolerance of acetylsalicylic acid, clopidogrel, ticlopidine, ticagrelor, prasugrel, heparin or antiproliferative agents from the limus-family of drugs; Subject with life expectation lower than 1 year; Any significant medical condition that, in the investigator's opinion, could interfere with the ideal participation of the subject in the study; Participation in other study in the past 12 months, unless a direct benefit to the subject can be expected. Impossibility of being treated with dual antiplatelet therapy for 12 months, based on investigator judgement.